Status:
UNKNOWN
the Gut Microbiome and Metabolomics in Chronic Lower extreMities Threatening Ischemia
Lead Sponsor:
Beijing Tsinghua Chang Gung Hospital
Conditions:
Chronic Limb-threatening Ischemia
Microtia
Eligibility:
All Genders
18+ years
Brief Summary
Intestinal floras and their metabolites are involved in progressing metabolic and cardiovascular diseases. However, currently, articles related to the relationship between intestinal floras and athero...
Detailed Description
This project aims to study the intestinal flora and its metabolites in patients with CLTI, explore whether CLTI patients and CAD patients have their own characteristic flora, analyze the microorganism...
Eligibility Criteria
Inclusion
- Control group: sex - and age-matched healthy people (without history of atherosclerotic plaque, coronary heart disease or stroke).
- Case group: resting pain for at least 2 weeks with at least one hemodynamic index: ABI\<0.4,AP\<50mmHg, TP or TCPO2\<30mmHg. Tissue defects (ulceration or gangrene) persisted for at least 2 weeks with at least one significant PAD objective evidence: ABI\<0.8, AP\<100mmHg, TP or TCPO2\<60mmHg.
Exclusion
- Patients with inflammatory bowel disease, autoimmune diseases, malignancies, infectious diseases, and severe liver and kidney dysfunction (cirrhosis, CKD stage 4 and 5).
- Patients with thromboembolic angiitis, arterial embolism, and takayasu.
- Patients who have used probiotics or antibiotics in the last 2 months.
- After interventional surgery and amputation below the knee or above knee.
Key Trial Info
Start Date :
November 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 15 2025
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06220994
Start Date
November 15 2021
End Date
May 15 2025
Last Update
January 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Tsinghua Chang Gung Hosipital
Beijing, Beijing Municipality, China, 100000